Eli Lilly Asks Supreme Court to Review Whistleblower Protection Law

Eli Lilly Challenges Whistleblower Provisions in Supreme Court Appeal

Indianapolis-based pharmaceutical giant Eli Lilly has petitioned the U.S. Supreme Court to restrict the False Claims Act’s whistleblower provisions, potentially reshaping how fraud cases against the government proceed. The company’s challenge stems from a $183 million judgment it faces over allegations of improperly reported drug prices to Medicaid.

The case originated in 2014 when whistleblower Ronald Streck filed a lawsuit under the False Claims Act’s qui tam provisions, which allow private citizens to sue on behalf of the government and receive a portion of any recovered funds. Streck alleged that Lilly misreported its Average Manufacturer Price for Medicaid rebate purposes, a claim that a federal jury supported in 2022 with a $61 million damages award that was subsequently trebled to approximately $183 million under the law’s provisions.

In its Supreme Court filing, Lilly argues that the False Claims Act’s qui tam mechanism unconstitutionally permits private individuals to pursue federal enforcement actions without proper presidential oversight. The pharmaceutical company contends this creates a system of “private bounty hunters, accountable to no one but themselves,” who can enforce federal law “on behalf of and in the name of the United States.”

The challenge comes at a time when False Claims Act cases are yielding significant financial recoveries for the federal government. The Justice Department reported that these cases returned a record $6.8 billion in settlements and judgments to taxpayers in fiscal year 2025, with whistleblower suits constituting a substantial portion of that total.

Lilly is also contesting the law’s fee-shifting provisions, which can require defendants to cover a whistleblower’s legal costs even when the government declines to intervene in the case. This aspect of the challenge addresses the financial incentives that currently exist for whistleblowers and their attorneys to pursue cases independently.

The Seventh Circuit Court of Appeals previously upheld the core findings against Lilly regarding falsity, materiality, and scienter (knowledge of wrongdoing). The company’s deadline to file its certiorari petition with the Supreme Court was extended to March 21, 2026.

Legal experts note that the Supreme Court’s decision on whether to hear the case could have far-reaching implications for both the pharmaceutical industry and government fraud recovery efforts. The False Claims Act, originally enacted during the Civil War to combat defense contractor fraud, has evolved into one of the government’s most powerful tools for addressing alleged fraud across numerous sectors, particularly healthcare.

“This challenge strikes at the heart of the False Claims Act’s effectiveness,” said one legal observer not involved in the case. “The qui tam provisions have been crucial in detecting fraud that might otherwise go undiscovered by government agencies with limited resources.”

Streck’s legal team has defended the jury’s decision, stating that it “sent money back to Medicaid and showed exactly why relators matter in policing fraud against public programs.” They argue that whistleblowers provide essential oversight in complex industries where fraudulent practices might otherwise remain hidden.

The Washington Legal Foundation, a business advocacy group that has long sought to narrow the False Claims Act, supports Lilly’s position. The organization has argued that the qui tam structure encourages overreaching private prosecutions and creates regulatory uncertainty for companies operating in heavily regulated industries like pharmaceuticals.

The pharmaceutical industry watches this case with particular interest, as drug manufacturers frequently face False Claims Act litigation over pricing, marketing, and regulatory compliance issues. A ruling limiting qui tam provisions could significantly reduce their legal exposure.

If the Supreme Court agrees to hear the case, its ruling would affect not only pharmaceutical companies but also defense contractors, healthcare providers, and other entities that receive federal funds. The decision could recalibrate the balance between empowering private citizens to expose fraud and maintaining appropriate governmental control over enforcement actions.

The Justice Department, which relies heavily on whistleblower cases to identify fraud, will likely defend the constitutionality of the qui tam provisions that have become a cornerstone of its fraud recovery efforts.

As the Supreme Court considers whether to take up this case, stakeholders across multiple industries await a decision that could fundamentally alter how fraud against the government is detected, prosecuted, and deterred.